Loading...

MedXY News - cardiovascular disease

MedXY AI/MedXY News/Tag: cardiovascular disease

MedXY News

EnglishTag

cardiovascular disease

57 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Spontaneous Preterm Birth as a Sentinel for Cardiovascular Mortality: Insights from a National Registry Study

Spontaneous Preterm Birth as a Sentinel for Cardiovascular Mortality: Insights from a National Registry Study

A large-scale Dutch cohort study reveals that women with a history of spontaneous preterm birth face a significantly elevated risk of cardiovascular mortality, with the highest risk observed in those delivering before 32 weeks of gestation.

Section: CardiologyJun 4, 2026

Thyroid Dysfunction Is a Cardiovascular Risk Multiplier, but Treatment Benefits Depend on Phenotype, Severity, and Age

Thyroid Dysfunction Is a Cardiovascular Risk Multiplier, but Treatment Benefits Depend on Phenotype, Severity, and Age

Thyroid dysfunction reshapes lipid metabolism, vascular tone, cardiac performance, and rhythm. Cardiovascular risk is clearest at the extremes of thyroid status, while treatment decisions in subclinical disease should remain individualized.

Section: CardiologyJun 3, 2026

Proteinuria in Preeclampsia and Long-Term Risk of Maternal Kidney and Cardiovascular Disease

Proteinuria in Preeclampsia and Long-Term Risk of Maternal Kidney and Cardiovascular Disease

Higher proteinuria in preeclampsia was linked to greater long-term risk of maternal hypertension and chronic kidney disease, with overall increased risk of cardiovascular disease as well.

Section: NephrologyMay 27, 2026

Six-Fold Higher Cardiovascular Risk: Eclampsia’s Early Postpartum Threat Demands Urgent Clinical Attention

Six-Fold Higher Cardiovascular Risk: Eclampsia’s Early Postpartum Threat Demands Urgent Clinical Attention

A nationwide study reveals that eclampsia patients face a 6.9-fold increased risk of cardiovascular disease readmission within the first year postpartum, with stroke risk nearly 13 times higher than normotensive patients. These findings und

Section: CardiologyApr 18, 2026

Beyond the Clot: Novel Proteomic Markers Reveal New Pathophysiological Pathways for Venous Thromboembolism

Beyond the Clot: Novel Proteomic Markers Reveal New Pathophysiological Pathways for Venous Thromboembolism

A large-scale proteomic meta-analysis across five cohorts identified 15 novel plasma protein markers for venous thromboembolism, highlighting the roles of the extracellular matrix, immunity, and vascular senescence in disease risk and offer

Section: CardiologyMar 31, 2026

Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management

Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management

This article explores the transformation of lipid management through PCSK9 inhibitors. From genetic discovery to landmark cardiovascular outcomes trials, we examine how monoclonal antibodies, RNA interference, and gene editing are redefinin

Section: CardiologyMar 22, 2026

Is Semaglutide Worth the Cost? Evaluating the Economic Reality of GLP-1s for Heart Disease Prevention

Is Semaglutide Worth the Cost? Evaluating the Economic Reality of GLP-1s for Heart Disease Prevention

A comprehensive simulation study evaluates the cost-effectiveness of semaglutide for secondary cardiovascular prevention in US adults without diabetes, finding significant health benefits but highlighting the need for price reductions to en

Section: CardiologyMar 20, 2026

Levothyroxine Monotherapy in Midlife Women: Long-Term SWAN Data Reassures on Cardiovascular Safety

Levothyroxine Monotherapy in Midlife Women: Long-Term SWAN Data Reassures on Cardiovascular Safety

A longitudinal analysis from the SWAN study indicates that women treated with levothyroxine for hypothyroidism do not face a higher risk of cardiovascular events compared to those without thyroid disease, providing clinical reassurance for

Section: Diabetes & EndocrinologyMar 12, 2026

GLP-1 Receptor Agonists in Primary Prevention: Emulated Clinical Trial Predicts 22% Reduction in Cardiovascular Events

GLP-1 Receptor Agonists in Primary Prevention: Emulated Clinical Trial Predicts 22% Reduction in Cardiovascular Events

This emulation study applies SELECT trial data to over 600,000 individuals, suggesting that GLP-1RAs could significantly reduce 10-year cardiovascular risk in high-risk obese populations without existing disease, offering a potential 22% re

Section: CardiologyMar 12, 2026

Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease: Leveraging the ‘Natural Stress Test’

Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease: Leveraging the ‘Natural Stress Test’

This review synthesizes findings on how pregnancy biomarkers, particularly sFlt-1 and hs-cTnI, serve as early indicators of long-term maternal cardiovascular risk, offering a unique window for sex-specific prevention.

Section: CardiologyMar 12, 2026

Beyond the Binary: The Evolving Consensus on the Spectrum of Primary Aldosteronism and Cardiovascular Risk

Beyond the Binary: The Evolving Consensus on the Spectrum of Primary Aldosteronism and Cardiovascular Risk

Recent data from the ARIC study and emerging expert consensus are redefining primary aldosteronism. Rather than a rare, all-or-nothing condition, it is now viewed as a broad spectrum where even subclinical elevations significantly increase

Section: CardiologyMar 7, 2026

Obesity Severity and Cardiovascular Trajectories: Insights from the Cross-Cohort Collaboration

Obesity Severity and Cardiovascular Trajectories: Insights from the Cross-Cohort Collaboration

This review synthesizes findings from a 21- **Compiling final edits** Now that I’ve structured the article, I’m focusing on the final touches, particularly the content for the “Highlights,” “Expert Commentary,” and the “Conclusion” sections

Section: CardiologyMar 2, 2026

The Rising Tide of Cardiovascular Disease: AHA’s 2050 Forecast for Women’s Heart Health

The Rising Tide of Cardiovascular Disease: AHA’s 2050 Forecast for Women’s Heart Health

A major AHA scientific statement forecasts a significant increase in cardiovascular disease and risk factors among U.S. women by 2050. It highlights rising rates of obesity and hypertension while emphasizing the urgent need for targeted int

Section: CardiologyMar 2, 2026

Beyond Information Delivery: Why Survivorship Care Plans Alone May Not Reduce Cardiovascular Risk in Cancer Survivors

Beyond Information Delivery: Why Survivorship Care Plans Alone May Not Reduce Cardiovascular Risk in Cancer Survivors

This article examines the CHIIP study, a randomized clinical trial evaluating whether survivorship care plan-based counseling improves cardiovascular risk factor control in childhood cancer survivors. Findings suggest that while documentati

Section: CardiologyFeb 24, 2026

Pregnancy as a Window to Longevity: Maternal Biomarkers at 29 Weeks Predict Long-Term Cardiovascular Risk

Pregnancy as a Window to Longevity: Maternal Biomarkers at 29 Weeks Predict Long-Term Cardiovascular Risk

A Danish cohort study demonstrates that specific pregnancy biomarkers, particularly sFlt-1 and hs-cTnI measured at 29 weeks, significantly enhance the prediction of long-term cardiovascular disease risk in women, independent of traditional

Section: CardiologyFeb 23, 2026

Semaglutide for Secondary CVD Prevention: Evaluating the Price of Clinical Success

Semaglutide for Secondary CVD Prevention: Evaluating the Price of Clinical Success

A simulation study reveals that while semaglutide significantly reduces cardiovascular events in adults with obesity, its current cost exceeds traditional cost-effectiveness thresholds, requiring an 18% price reduction for broader economic

Section: CardiologyFeb 5, 2026

Haptoglobin 1-1 and Low Protein Levels: Identifying the Lowest Cardiovascular Risk in Type 2 Diabetes

Haptoglobin 1-1 and Low Protein Levels: Identifying the Lowest Cardiovascular Risk in Type 2 Diabetes

A FIELD sub-study reveals that while higher haptoglobin levels increase cardiovascular risk—particularly in those with the HP 1-1 phenotype—fenofibrate’s protective effects remain consistent regardless of haptoglobin status, challenging pre

Section: CardiologyFeb 4, 2026

Oral Semaglutide Slows eGFR Decline in Patients with Type 2 Diabetes and High Cardiovascular Risk: Insights from the SOUL Trial

Oral Semaglutide Slows eGFR Decline in Patients with Type 2 Diabetes and High Cardiovascular Risk: Insights from the SOUL Trial

The SOUL trial demonstrates that oral semaglutide significantly slows the annual decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and cardiovascular disease, despite not meeting the primary composite k

Section: CardiologyFeb 3, 2026

Lipoprotein(a) and the 30-Year Horizon: Redefining Long-Term Cardiovascular and Stroke Risk in Women

Lipoprotein(a) and the 30-Year Horizon: Redefining Long-Term Cardiovascular and Stroke Risk in Women

Longitudinal data from the Women’s Health Study reveal that elevated Lipoprotein(a) is a potent, independent predictor of myocardial infarction and ischemic stroke over three decades, suggesting a critical need for universal screening in pr

Section: CardiologyJan 25, 2026

Interleukin-6 Inhibition: A New Frontier in Reducing Residual Cardiovascular and Renal Risk

Interleukin-6 Inhibition: A New Frontier in Reducing Residual Cardiovascular and Renal Risk

Recent clinical evidence identifies Interleukin-6 (IL-6) as a critical driver of cardiovascular events. The ZEUS trial and recent LoDoCo2 analyses suggest that targeting IL-6 with ziltivekimab may significantly reduce risk for patients with

Section: CardiologyJan 17, 2026

Prev 1 2 3 Next